Rad57 Activators

Rad57 Activators encompasses a diverse range of compounds that exert their influence on DNA repair pathways, not by directly stimulating Rad57, but through the creation of cellular conditions that necessitate the increased activity of homologous recombination processes in which Rad57 is presumed to be involved. Topoisomerase I and II, as well as drugs that cause DNA damage such as alkylating agents and intercalating agents. When these compounds are introduced into a cellular environment, they disrupt the normal repair mechanisms or induce damage that requires the HR pathway for resolution. Consequently, this indirect action can lead to an upsurge in the demand for HR-mediated repair, thereby increasing the cellular reliance on HR proteins, including Rad57, to maintain genomic integrity.

These compounds are characterized by their ability to either stall competing DNA repair pathways or directly inflict DNA lesions that are typically repaired by HR. For exampleOlaparib, Rucaparib, and PJ-34 impede the base excision repair machinery, thus indirectly prompting the cell to depend more on HR for DNA damage repair, which may upregulate Rad57 activity. Similarly, agents like Cisplatin and MMS create DNA cross-links and alkylation damage, respectively, which HR is uniquely suited to repair. I